Homology Medicines: 3Q Earnings Snapshot

November 12, 2019 GMT

BEDFORD, Mass. (AP) _ Homology Medicines Inc. (FIXX) on Tuesday reported a loss of $29.6 million in its third quarter.

The Bedford, Massachusetts-based company said it had a loss of 67 cents per share.

The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 58 cents per share.

The gene editing company posted revenue of $441,000 in the period.

Homology Medicines shares have declined 49% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $11.47, a decrease of 43% in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FIXX at https://www.zacks.com/ap/FIXX